ATP6V1C2

Across TCGA pan-cancer cohorts, ATP6V1C2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP6V1C2 data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ATP6V1C2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATP6V1C2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

LSCC, UCEC, and CCRCC are the cancer types where ATP6V1C2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	1.000	0.450	.024	8	view →
UCEC	OS	Tertile	All	1.000	0.876	.028	6	view →
CCRCC	DFS	Median	III,IV	0.754	0.454	.021	6	view →
LUAD	OS	Median	III,IV	0.379	0.819	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP6V1C2–LSCC (OS)

Open the LSCC breakdown →